Company / Return on Equity (ROE)
Twist Bioscience Corp Return on Equity (ROE) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-16.4%
FY2025
5-year range
-44.2% / -16.4%
FY2021-FY2025
Trend
+62.8%
vs FY2024
Sector context
#71 of 190
Health Care
What the data says
Twist Bioscience Corp reports negative total equity of -16.4% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-16.4% in FY2025 with a 5-year CAGR of +25.2%.
Improved from -32.8% to -16.4% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +11.2pp
- 5-Year Change
- +25.2pp
- 10-Year Change
- -
Sector benchmark
#71 of 190 in Health CareTop 37% of 190This company -16.4% Sector average -50.3%
▼
+67.3% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 62.8% year-over-year.
- Currently 33.8pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -16.4% | +62.8% |
| FY2024 | -44.2% | -34.6% |
| FY2023 | -32.8% | -18.9% |
| FY2022 | -27.6% | -5.4% |
| FY2021 | -26.2% | +37.1% |
| FY2020 | -41.6% | +41.2% |
| FY2019 | -70.8% | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026